Vogenx (NASDAQ:VOGX) Stock Gets Downgrade from Wall Street Zen

Vogenx (NASDAQ:VOGX – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other research firms have also recently issued reports on VOGX. Weiss Ratings began coverage on Vogenx in a research report on Monday. They issued a “sell (e-)” rating for the company. Zacks Research upgraded Vogenx to a “hold” rating in a research note on Monday, September 28th. JonesTrading initiated coverage on Vogenx in a report on Tuesday, September 1st. They set a “buy” rating and a $55.00 target price on the stock. Finally, WBB Securities assumed coverage on Vogenx in a research note on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $48.50.

Check Out Our Latest Research Report on Vogenx

Vogenx Price Performance

Shares of NASDAQ:VOGX opened at $16.67 on Friday. Vogenx has a 52-week low of $12.95 and a 52-week high of $38.41. The firm has a 50-day moving average price of $22.03.

Vogenx (NASDAQ:VOGX – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. On average, sell-side analysts expect that Vogenx will post -0.61 EPS for the current year.

Vogenx Company Profile

(Get Free Report)

Vogenx Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc. is based in RALEIGH, NC.

Further Reading

Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.